Bayer has secured a significant legal victory in the United States, with the Supreme Court ruling in its favor in a long-running dispute over the cancer risks associated with its glyphosate-based herbicide Roundup.
The high court's decision marks a pivotal moment in the billions of dollars in litigation the company has faced since acquiring Monsanto in 2018.
The ruling effectively dismisses a central case that had been used by plaintiffs to argue for broader liability, providing a measure of relief to investors who have watched the stock weigh under the burden of ongoing lawsuits.
While the Supreme Court did not rule on the scientific merits of glyphosate's safety, its procedural decision limits the scope of future claims and sets a precedent that could streamline the resolution of remaining cases.
Bayer shares reacted positively to the news, reflecting investor sentiment that the legal overhang is beginning to lift.
The German DAX, which had already posted solid gains earlier in the session driven by broader geopolitical relief, saw additional support from Bayer's performance.